Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. - Wikidata - awgldk - TriplyDB

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.

http://www.wikidata.org/entity/Q33617841

about

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy γδ T cell and other immune cells crosstalk in cellular immunity γδ T cells in cancer immunotherapy Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions.Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells The effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the disease Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation.The TCR γδ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vδ1 and Vδ2 T cells.Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications.At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.Potential Use of γδ T Cell-Based Vaccines in Cancer Immunotherapy.Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2.Promising new strategies for hepatocellular carcinoma.Bone-Targeted Therapies in Cancer-Induced Bone Disease.γδ T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors.[Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape].γδ T Cells: Unexpected Regulators of Cancer Development and Progression.Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood γδ T cells.Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity.Dendritic Cells Are Critical for the Activation and Expansion of Vδ2 T Cells After Allogeneic Hematopoietic Transplantation Zoledronic acid modulates maturation of human monocyte-derived dendritic cells

P2860

Q26781175-8A28CF03-FC01-4AA1-86CF-AF0FF7AA47D7 Q27007775-AF5F626E-FE2F-4F6C-AE3A-67CAA7F4F3CF Q28068988-1871A121-33AC-4DC0-8D0A-D4A384DE431A Q33938500-1D3A846E-3566-4ED1-AAAA-6463E6771BE8 Q34077388-5851EB7F-F693-4EA2-A2AF-C85AE1FCAB6E Q34743969-451C3C86-B554-4B8C-BD27-B16A74BC05CF Q35677421-E18FCAC0-5C04-4D87-9F49-C703A176748B Q35886565-FAF896CA-88FF-417E-BE36-0B65668CF0AA Q36471673-83968128-10AB-404B-BD10-02B87E68D2BB Q36734208-53F9420B-2470-425F-AD01-3CF065013077 Q37028734-C644A06D-44E0-43C3-B60C-2FC5C6DBAA8F Q37433992-087C81EC-E95A-4C94-BFEA-2C5844CC0A3A Q37655345-70389C26-6DD0-445C-8279-931C2AD9634C Q37876363-45111B86-9EE3-46D3-9680-EE85EBAE77C8 Q37917774-11B9F94B-B553-4205-B181-51F074DC66B3 Q38051730-D6A66050-2B79-42F8-B799-84B5D25E62A9 Q38053396-52B89F6D-E544-4B6C-B581-BA1AFC8E7F61 Q38149725-0D96137F-073F-4DE3-B395-56EA2570253A Q38265506-24C2A6E0-5552-4E68-A97F-DC2166B8AF3B Q38819970-CFC6B0A4-DF17-472C-95A7-42530C679A33 Q38936589-F0E4F136-6B6E-4A18-8759-A2A8D03F43B1 Q48110513-A2F00DA6-001E-488A-9F54-5F6BF78D7DE1 Q52649705-81E5BB1B-70ED-4D5D-BB2C-B61B2D0BD7E4 Q53235682-02CAE75F-5916-4AB9-AF05-02532D96CD47 Q54326921-07442F68-5324-41B1-8688-8A7A11EA6C7C Q54691443-F82E13D5-2CC9-4663-BDBF-E07297C8A8D2 Q55291915-B42D876E-C074-4F9E-A3CE-B453909DFC02 Q59137745-4AD956ED-DB7F-44E6-AF79-3991634B6EED Q59242355-628F5F16-8C67-46B5-AD45-98DBC6D37760

P2860

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.

http://www.wikidata.org/entity/Q33617841

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@ast

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@en

type

label

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@ast

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@en

prefLabel

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@ast

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@en

P1433

Q33617841-D8B9CFEA-0FF6-4747-8A41-A41FE2A26999

P1476

Q33617841-ED06F609-A864-4035-9EF1-C6FA7AAC36CF

P2093

Q33617841-13C571A8-C1B2-4A5D-8577-87DB1E596758

Q33617841-28303A6C-FC17-41C2-9BFB-3FBC960C42EC

Q33617841-2E0A6B64-6F48-4968-ABBA-471CB11747E7

Q33617841-5EE03ECC-ACB1-468E-B339-4EB86EEC15C3

Q33617841-606A3170-6D4A-4E25-A13C-BA04C2825262

Q33617841-B72B096A-5D7F-4810-B77F-CE250CF98549

Q33617841-B743970A-4BB4-41CB-8FDF-54F8E1C09C2B

Q33617841-D34B1CCE-35C3-4AC8-8A27-DB25E864BD08

Q33617841-D8D278BB-92DB-4A1F-9D79-A0CB955318AB

Q33617841-E280653A-166A-4DBB-850A-04913B7AD214

P2860

Q33617841-14C51FDF-3E7C-4F5C-85E2-ED95C8647164

Q33617841-93D6F8EE-34D6-4142-8ED3-465E4D0212CD

Q33617841-9FDDA192-980A-4FE4-A8CE-74C4E85C1043

P2888

Q33617841-2A82663A-DFB5-430E-9C72-1719E0BCC62E

P304

Q33617841-B45A4D68-703A-47FA-AC57-AD7048D0AFCC

P31

Q33617841-D0B1022D-3757-4B42-9CF9-9D9F0290D5DF

P356

Q33617841-B6265841-3FEF-4DD0-B859-F66A11C9AAC6

P433

Q33617841-54962835-0E25-4810-BED7-7D6AE04E1EC2

P478

Q33617841-396C6C77-7F60-439A-861B-B358265EA56D

P577

Q33617841-638E8E0A-3115-4413-835F-91590062C944

P5875

Q33617841-8EC9A68C-D6FB-48E6-B483-C57AF19C1E2A

P6179

Q33617841-14766657-0D1D-4C14-9ACC-8CFCD4506143

P698

Q33617841-3DF9DABF-0BE1-4DF2-80C1-5EEC3CB12072

P921

Q33617841-3CDC1277-D2D5-435B-B81E-A059A43533AE

P356

S00262-010-0887-0

P1433

Cancer Immunology, Immunotherapy

P1476

Aminobisphosphonate-pretreated ...... y in advanced cancer patients.

@en

P2093

Bruno Turlin

http://www.w3.org/2001/XMLSchema#string

Cécile Thomas de La Pintière

http://www.w3.org/2001/XMLSchema#string

Florian Cabillic

http://www.w3.org/2001/XMLSchema#string

Françoise Bouet-Toussaint

http://www.w3.org/2001/XMLSchema#string

Hannu Mönkkönen

http://www.w3.org/2001/XMLSchema#string

Jukka Mönkkönen

http://www.w3.org/2001/XMLSchema#string

Karim Boudjema

http://www.w3.org/2001/XMLSchema#string

Nathalie Rioux-Leclerc

http://www.w3.org/2001/XMLSchema#string

Olivier Toutirais

http://www.w3.org/2001/XMLSchema#string

Pascale Daniel

http://www.w3.org/2001/XMLSchema#string

P2860

V gamma 9V delta 2 T cell response to colon carcinoma cells.

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation.

P2888

s00262-010-0887-0

P304

1611-1619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0887-0

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44804177

http://www.w3.org/2001/XMLSchema#string

P6179

1012330785

http://www.w3.org/2001/XMLSchema#string

P698

20582413

http://www.w3.org/2001/XMLSchema#string

P921